What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...

A 21-year-old engineering student from Delhi, suffering from severe allergic asthma and rashes, successfully underwent personalised treatment in Hyderabad. Combining immunotherapy, probiotics and ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

There’s often a debate regarding which is the most effective treatment for cough Our experts are going to answer this for you ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

US FDA approves GSK’s Exdensur for the treatment of severe asthma: London, UK Thursday, December 18, 2025, 11:00 Hrs [IST] GSK plc announced that the US Food and Drug Administra ...

Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...

Oral corticosteroids present significant long-term risks with uncertain evidence for improving asthma outcomes, according to data presented at the American College of Allergy, Asthma & Immunology ...

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...